secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2026-04-08T23:59:59+00:00
Accession:  0001493152-26-015662
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA Biotechnology: $33M raise fully funds pivotal Phase 3 trial for ateganosine in NSCLC
--------------------------------------------------------------------------------

- Net proceeds from $33M March 2026 common stock offering expected to fully fund pivotal Phase 3 trial (THIO-104) for ateganosine in third-line NSCLC.
- FDA granted Fast Track designation for ateganosine, a dual mechanism telomere-targeting agent, for third-line NSCLC treatment.
- Statistical assessments based on Phase 2 data point to high probability of technical success in Phase 3 full approval trial.
- Interim Phase 3 data expected next year; may support FDA discussion for early full commercial approval in third-line NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000149315226015662/0001493152-26-015662-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000149315226015662/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-015662

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer